Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase 3 study of Niyad™ (nafamostat)

Next Previous
Search
Trial Profile

A phase 3 study of Niyad™ (nafamostat)

Status: Recruiting
Phase of Trial: Phase III

Latest Information Update: 04 Apr 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Nafamostat (Primary)
  • Indications Disseminated intravascular coagulation
  • Focus Registrational; Therapeutic Use
  • Acronyms NEPHRO CRRT

Most Recent Events

  • 31 Mar 2025 According to an AcelRx Pharmaceuticals media release, Cash and investments at December 31, 2024 of $8.9 million, together with the private placement financing recently announced of up to $14.8 million, expected to provide capital through target completion of the NEPHRO study in the fourth quarter of 2025.
  • 31 Mar 2025 According to a Talphera media release, company anticipates to completed this study by the end of 2025.
  • 31 Mar 2025 According to a Talphera media release, company announced that The U.S. Food and Drug Administration (FDA) agreed to reduce the number of patients in the NEPHRO CRRT study from 166 to 70 patients, of which 6 patients are already enrolled.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top